Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 5, 2005, Pages 965-967

  Kim, Jung Mogg ^a   Kim, Joo Sung ^b   Kim, Nayoung ^b   Jung, Hyun Chae ^b   Song, In Sung ^b  

^a Hanyang University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

gyrA; Mutation; QRDR; Resistance

Indexed keywords

AGAR; BACTERIAL DNA; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGAR MEDIUM; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CODON; DILUTION; DNA DETERMINATION; DNA SEQUENCE; GASTRITIS; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HELICOBACTER PYLORI; HUMAN; KOREA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; SEQUENCE ANALYSIS; STOMACH BIOPSY; STOMACH MUCOSA;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KOREA; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; POINT MUTATION; QUINOLINES; SEQUENCE ANALYSIS, DNA;

EID: 27744489118     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki334     Document Type: Article

References (10)

1. Cammarota G, Cianci R, Cannizzaro O et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-43.
2. Cheon JH, Kim N, Lee DH et al. Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. Kor J Gastroenterol 2005; 45: 111-7.
3. Kim JM, Kim JS, Jung HC et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004; 48: 4843-7.
4. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing - Twelfth Informational Supplement M100-S12. NCCLS, Wayne, PA, USA, 2002.
5. Tankovic J, Lascols C, Sculo Q et al. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47: 3942-4.
6. Moore RA, Beckthold B, Wong S et al. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995; 39: 107-11.
7. Fujimura S, Kato S, Iinuma K et al. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol 2004; 53: 1019-22.
8. Debets-Ossenkop YJ, Herscheid AJ, Pot RG et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999; 47: 511-5.
9. Cabrita J, Oleastro M, Matos R et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-31.
10. Heep M, Kist M, Strobel S, et al. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 538-41.